Navigation Links
Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
Date:2/11/2008

re reported.

Results of the pixantrone phase III clinical trial in aggressive, relapsed non-Hodgkin's lymphoma (NHL), known as the EXTEND or PIX301 trial, are expected in the summer of 2008. Depending on the results of this trial, CTI may begin a rolling New Drug Application (NDA) submission for pixantrone in the second half of the year. CTI has closed enrollment on its other clinical trials of pixantrone, including the RAPID trial, a first-line randomized phase II study of CHOP-R versus CPOP-R in previously untreated aggressive NHL patients, and the PIX303 trial, a study of fludarabine, pixantrone and rituximab (FP-R) compared to the combination of fludarabine and rituximab (F-R) in the treatment of patients who have received at least one prior treatment for indolent NHL.

"Based on feedback from both our partner Novartis and from a panel of oncology experts, all agreed the best step for the Company is to focus resources on obtaining XYOTAX and pixantrone approval with existing or completing phase III trials before making additional substantial investments in alternative indications for these products. Combined with reductions in phase III clinical trials costs for XYOTAX and pixantrone, we are projecting net cash operating expenses of $77 million in 2008," Bianco added.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated for the treatment of patients with relapsed or refractory low-grade or follicular B-cell NHL, including patients with Rituximab-refractory NHL. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most seri
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO CEO & Investor Conference
2. Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference
3. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
4. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
5. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
6. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
7. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
8. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
9. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
10. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
11. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... This is a professional and in-depth ... (IPA) industry. The report provides a basic overview ... chain structure. Global market analysis and Chinese domestic ... history, developments, trends and competitive landscape of the ... situation is also offered. , The report ...
(Date:9/23/2014)... Marktech Optoelectronics has introduced the MTE280xxx series, its ... 280 nm wavelength range. This series joins Marktech’s current ... to 405nm. These new devices are suitable for applications ... Mark Campito, Marktech’s CEO states that “what makes this ... that we offer it in one of the largest ...
(Date:9/22/2014)... treated with a statin in the hospital after suffering ... survive than those who were not, according to a ... study was conducted by the same researchers who recently ... survival in victims of ischemic stroke., Ischemic stroke is ... vessel that blocks blood from reaching areas of the ...
(Date:9/22/2014)... cell fragments whose job it is to stop bleeding, ... But they can "feel" the physical environment around them, ... Platelets respond to surfaces with greater stiffness by increasing ... other platelets and other components of the clotting system, ... give them credit for, in that they are able ...
Breaking Biology Technology:(IPA) Isopropanol Industry International & China Development Trend Analysis Now Available at DeepResearchReports.com 2(IPA) Isopropanol Industry International & China Development Trend Analysis Now Available at DeepResearchReports.com 3Marktech Introduces its New Line of Deep UV Emitters 2Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2Platelets modulate clotting behavior by 'feeling' their surroundings 2
... NIOX MINO(R) Set to Dramatically Improve Airway Inflammatory Disease ... Management through Personalized Inflammation Control, NEW PROVIDENCE, N.J., ... that NIOX MINO (http://www.nioxmino.com ), a,hand- held point-of-care ... cleared by the U.S. Food and Drug Administration (FDA).,Physicians ...
... RICHMOND, Va., March 4 Insmed Inc. (Nasdaq,CM: INSM), a developer of ... December 31, 2007., Full-Year 2007 and Recent Company Highlights, ... Completed development of INS-19 (Granulocyte Colony Stimulating ... these products to ...
... First Joint U.S. National Modeling and ... Simulation Meeting on March 11-12, 2008, ... PHST ), a leading provider of software, strategic,consulting, ... its broad-based participation at the inaugural,meeting of the American ...
Cached Biology Technology:FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma 2FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma 3FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma 4Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 2Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 3Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 4Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 5Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 6Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 7Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 8Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 9Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 10Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 11Pharsight Makes Strong Contribution to Inaugural American Conference on Pharmacometrics 2Pharsight Makes Strong Contribution to Inaugural American Conference on Pharmacometrics 3
(Date:9/23/2014)... or isoforms in microRNAs (miRNAs) before, but assumed that ... in the journal Oncotarget this month, shows ... on geographic subpopulations and gender and that the most ... the one typically listed in the public databases. , ... common than we had previously assumed. The fact that ...
(Date:9/23/2014)... When the body forms new tissues during the ... with each other. For years, scientists believed this ... at Carnegie Mellon University and the University of ... communication is equally if not more crucial. ... the Proceedings of the National Academy of ...
(Date:9/23/2014)... Research by Rice University scientists who are fighting a ... be a clinician,s most powerful ally. , "Recent research ... cyberwarfare against the immune system, and we studied the ... how we might turn the tables on cancer," said ... this week in the Early Edition of the ...
Breaking Biology News(10 mins):Slight alterations in microRNA sequences hold more information than previously thought 2Slight alterations in microRNA sequences hold more information than previously thought 3The mechanics of tissue growth 2Immune system is key ally in cyberwar against cancer 2Immune system is key ally in cyberwar against cancer 3
... single female is nearby, female antbirds will sing over the ... keep their messages from getting through, according to a new ... , a Cell Press publication. Males respond to that interruption ... first evidence that such "signal jamming" and "jamming avoidance" occur ...
... at Birmingham professor Lisa Guay-Woodford, M.D., will receive ... Jean Kaplan International Prize for Advancement in the ... The PKD Foundation and the International Society of ... contributions to the field of polycystic kidney disease ...
... of who will carry the burden but could instead ... economic modeling presented today at "Climate Change: Global Risks, ... Contrary to current cost models for lowering ... of researchers from the University of Cambridge conclude that ...
Cached Biology News:Female birds 'jam' their mates' flirtatious songs 2UAB's Lisa Guay-Woodford earns top international nephrology prize 2UAB's Lisa Guay-Woodford earns top international nephrology prize 3Fighting global warming offers growth and development opportunities 2Fighting global warming offers growth and development opportunities 3
The novel and unique HCTplus delivers unmatched information-rich data-dependent LC/MSn data for todays challenge in proteomics and metabonomics work....
... new chapter to a 40-year ... 7890A GC gives you everything ... lab to the next level ... including advanced separation capabilities, powerful ...
... the six short years since publication of ... Walkers widely acclaimed Protein Protocols Handbook, there ... protein biochemistry. In recognition of the level ... rapid evolution of new methodologies directed to ...
... often call for critical, but time-consuming ... refines siRNA transfection protocols resulting in ... can be used to efficiently transfect ... without increased cytotoxicity. From start ...
Biology Products: